Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FSKE6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,369
Award facts
- Contract value 100% obligated
- $2,368.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,368.83 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The contract, issued on November 25, 2025, with an ultimate completion date of December 17, 2025, was awarded without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to provide the Department of Defense with a comprehensive pharmaceutical supply chain supporting military healthcare facilities worldwide. Under this program structure, DMS Pharmaceutical Group serves as a critical regional prime vendor contractor, authorized to fulfill firm fixed-price delivery orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. Xolair, a biologic immunosuppressant agent, supports the specialized pharmaceutical requirements of the federal military medical system and reflects the company's demonstrated capability to supply diverse therapeutic categories across multiple product lines to federal agencies.
Quick answers
Who was awarded contract SPE2DR26FSKE6?
SPE2DR26FSKE6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FSKE6 worth?
The government has obligated $2,369 on SPE2DR26FSKE6.
Is contract SPE2DR26FSKE6 an order under another contract?
Yes. SPE2DR26FSKE6 is a delivery order under SPE2DR25D9317, an indefinite delivery contract.
Was contract SPE2DR26FSKE6 competed?
The extent of competition for SPE2DR26FSKE6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award